A Top Puma Bio Exec Resigns Ahead of FDA Panel, Analysts Defend With Conflicting Stories - TheStreet
Puma Biotechnology Third Quarter 2022 Earnings: Beats Expectations
PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence
Puma Biotechnology, Inc. 2020 Current Report 8-K
Puma Biotechnology
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
PUMA BIOTECHNOLOGY, INC. : PBYI Stock Price | US74587V1070 | MarketScreener
Puma Biotechnology: Still Bullish At These Prices (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology - Crunchbase Company Profile & Funding
PumaBiotech (@pumabiotech) / Twitter
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting
Puma Biotechnology
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Puma Biotechnology - Crunchbase Company Profile & Funding
Federal Jury Awards Puma Biotechnology Investors Damages in Securities Class-Action Verdict - Los Angeles Business Journal
Puma Biotechnology | citybiz
Puma Biotechnology up 15% after quarterly earnings beats (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology (PBYI) Presents At Barclays Global Healthcare Virtual Conference (NASDAQ:PBYI) | Seeking Alpha
Is Puma Biotechnology (PBYI) Stock a Solid Choice Right Now?
Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Profit Outlook
Puma Biotech plunges on drug side effects
Puma Biotechnology
PumaBiotech (@pumabiotech) / Twitter
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotechnology Surging
